Cargando…

Estimating the Costs of Opioid Abuse and Dependence from an Employer Perspective: a Retrospective Analysis Using Administrative Claims Data

BACKGROUND: Opioid abuse and dependence is problematic across many age groups, including the working-age population and their dependents. Little is known, however, about the economic costs of opioid abuse/dependence imposed on employers, who pay for a substantial portion of healthcare costs through...

Descripción completa

Detalles Bibliográficos
Autores principales: Rice, J. Bradford, Kirson, Noam Y., Shei, Amie, Cummings, Alice Kate G., Bodnar, Katharine, Birnbaum, Howard G., Ben-Joseph, Rami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287687/
https://www.ncbi.nlm.nih.gov/pubmed/24919646
http://dx.doi.org/10.1007/s40258-014-0102-0
Descripción
Sumario:BACKGROUND: Opioid abuse and dependence is problematic across many age groups, including the working-age population and their dependents. Little is known, however, about the economic costs of opioid abuse/dependence imposed on employers, who pay for a substantial portion of healthcare costs through their contributions to employer-sponsored health insurance and are also affected by indirect costs such as those due to disability and workplace absenteeism. OBJECTIVE: To provide a comprehensive, current estimate of the economic burden of prescription opioid abuse/dependence to employers. METHODS: Administrative claims from beneficiaries covered by large self-insured companies throughout the USA were used to identify patients, including employees and dependents, who were diagnosed with opioid abuse and/or dependence (‘abusers’) between 2006 and 2012. Healthcare and work-loss costs for abusers were assessed over a 12-month period and compared with those for patients not diagnosed with abuse (‘comparison patients’), using propensity score matching. RESULTS: 7,658 matched pairs of abusers and comparison patients were analysed. Relative to comparison patients, abusers had significantly higher annual healthcare resource utilization, leading to US$10,627 in per-patient incremental annual healthcare costs. Additionally, abusers had US$1,244 in excess annual work-loss costs. Together, this implies an employer burden for diagnosed abuse of US$1.71 per member per month. CONCLUSION: Opioid abuse/dependence impose a substantial economic burden on employers.